Medizentrum Essen Borbeck | Essen, Germany

Research site

(Unclaimed)

Location

Huelsmannstr. 6, Essen, North Rhine-Westphalia, Germany

Site insights

Top conditions

Top treatments

Orforglipron

LY3502970

Tirzepatide

LY3298176

Astegolimab

Bococizumab

RTX-GRT7039

Apixaban

Allopurinol

LY3841136

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 35 total trials

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Enrolling

Hypertension

Drug: Orforglipron

Drug: Placebo

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants w...

Enrolling

Overweight

Obesity

Drug: Placebo

Drug: Orforglipron

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Enrolling

Hypertension

Overweight or Obesity

Drug: Placebo

Drug: Orforglipron

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Enrolling

Hypertension

Drug: Orforglipron

Drug: Placebo

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (ENLIGHTEN-1)

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes...

Enrolling

Overweight

Obesity

Drug: Placebo

Drug: Eloralintide

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overw...

Enrolling

Overweight

Obesity

Drug: Orforglipron

Drug: Placebo

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with...

Enrolling

Overweight

Obesity

Drug: Orforglipron

Drug: Placebo

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiova...

Enrolling

Chronic Kidney Disease

Atherosclerosis Cardiovascular Disease

Drug: Orforglipron

Drug: Placebo

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5)

The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study wi...

Active, not recruiting

Obesity

Drug: Retatrutide

Drug: Tirzepatide

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Tirzepatide

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to assess the long-term safety and to explore the efficacy of astegolimab in participants with chronic obstructive pulmo...

Enrolling

Chronic Obstructive Pulmonary Disease

Drug: Astegolimab

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Active, not recruiting

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

Status recently updated

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type...

Not yet enrolling

Enrolling

Overweight and/or Obesity

Overweight

Drug: PF-08653944

Other: Placebo